	US 11,913,938 B2
	Methods to assess the risk of being affected by prostate cancer
Gianluigi Taverna, Rozzano (IT); Fabio Grizzi, Rozzano (IT); Laura Maria Teresa Capelli, Milan (IT); Carmen Bax, Milan (IT); Selena Sironi, Milan (IT); and Lidia Giuseppina Eusebio, Milan (IT)
Assigned to HUMANITAS MIRASOLE S.P.A., Rozzano (IT); and POLITECNICO DI MILANO, Milan (IT)
Appl. No. 17/435,941
Filed by HUMANITAS MIRASOLE S.P.A., Rozzano (IT); and POLITECNICO DI MILANO, Milan (IT)
PCT Filed Mar. 3, 2020, PCT No. PCT/EP2020/055555 § 371(c)(1), (2) Date Sep. 2, 2021, PCT Pub. No. WO2020/178284, PCT Pub. Date Sep. 10, 2020.
Claims priority of application No. 19160856 (EP), filed on Mar. 5, 2019.
Prior Publication US 2022/0146493 A1, May 12, 2022
Int. Cl. G01N 33/493 (2006.01); G01N 27/12 (2006.01); G01N 33/574 (2006.01)

CPC G01N 33/493 (2013.01) [G01N 27/12 (2013.01); G01N 33/57434 (2013.01)]

20 Claims

1. An in vitro method to assess the risk that a subject is affected by prostate cancer, such method comprising:

a) providing a urine sample from said subject which does not comprise the last jet of a naturally voided urine sample;

b) heating the sample to above 50° C. in a closed, humidity-controlled environment;

c) analysing the headspace of the sample heated in step b), under humidity control, with at least 3 Metal Oxide Semiconductor (MOS)-based gas sensors, wherein the metal oxide of the first gas sensor is pure or doped SnO₂, the metal oxide of the second sensor is pure or doped ZnO and the metal oxides of the third sensor are pure or doped SnO₂, pure or doped TiO₂and pure or doped Nb₂O₅;

d) comparing the values obtained in step c) to reference values for each sensor, thereby assessing the risk that a subject is affected by prostate cancer.